AIM: The clinical value of @entity1605 ( @entity1605 ) after endoscopic submucosal dissection (ESD) has been doubted continuously. The aim of this study was to assess the effectiveness of @entity1605 based on the risk of delayed @entity548 after ESD. METHODS: A total of 310 lesions of @entity356 treated by ESD were reviewed. The lesions were divided into two groups based on the risk of post-procedural @entity548 estimated by Forrest classification. The high risk of rebleeding group (Forrest   Ia,   Ib and IIa) required endoscopic treatment, while the low risk of rebleeding group (Forrest IIb, IIc and III) did not. Delayed @entity548 after ESD was investigated. RESULTS: Sixty-six lesions were included in the high risk of rebleeding group and 244 lesions in the low risk of rebleeding group. There were no significant differences in delayed @entity548 between the high risk group (1/66) and the low risk group (1/244) (P = 0.38). The high risk of rebleeding group tended to be located more often in the mid-third and had higher appearance of flat or @entity308 shape than the low risk group (P = 0.004 and P = 0.006, respectively). CONCLUSION: @entity1605 with pre-emptive prophylactic endoscopic treatment is still effective in preventing delayed @entity548 after ESD.

Second-look endoscopy with prophylactic hemostasis is still effective after endoscopic submucosal dissection for XXXX .

@entity308 :: ('MESH:D003866', 'Disease') :: ['depressed'] @entity1605 :: ('OMIM:217000', 'Disease') :: ['SLE', 'second-look endoscopy'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric epithelial neoplasms'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']
@entity356 :: (MESH:D013274,Disease) :: ['gastric neoplasm']
